Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Target Oncol
; 17(6): 643-653, 2022 11.
Article
in En
| MEDLINE
| ID: mdl-36272060
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Target Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Affiliation country:
Japan